Introduction {#S0001}
============

Gastric cancer (GC) is the fifth most common malignancy, and the third leading cause of cancer-related deaths (723,100 in 2012) globally.[@CIT0001] Currently, a series of risk factors, such as dietary factors, *Epstein-Barr* virus, and *Helicobacter pylori* infection have been identified for GC. Moreover, an increasing amount of evidence show that genetic factors and their downstream effects on cellular processes play important roles in GC progression, but, the pathogenesis of GC still remains complex.[@CIT0002],[@CIT0003] Additionally, despite the advances in cancer diagnosis and treatment, the prognosis of GC patients still remains unsatisfactory with the 5-year survival rate less than 30% due to its aggressive behavior.[@CIT0004] Hence, it is urgent to identify novel biomarkers and effective therapeutic targets for patients with GC.

TNF-like ligand 1A (TL1A; also known as TNFSF15 or VEGI), is a unique cytokine produced by endothelial cells, T cells, macrophages, monocytes and dendritic cells, which inhibits proliferation and angiogenesis of endothelial cells.[@CIT0005],[@CIT0006] *TL1A* has been reported to be involved in modulating vascular homeostasis and inflammation.[@CIT0007] Previous studies have reported that *TL1A* plays an important role in a variety of autoimmune inflammatory diseases, such as rheumatic arthritis (RA), asthma and inflammatory bowel disease.[@CIT0008] Additionally, *TL1A* is involved in the development of multiple tumor types,[@CIT0009],[@CIT0010] and is recognized as the potential therapeutic target for cancer therapy.[@CIT0011],[@CIT0012] Recently, reduced *TL1A* expression was found to be associated with poor prognosis in breast cancer patients.[@CIT0011] However, the role of *TL1A* in GC progression remains unclear.

In the present study, in order to reveal the potential role of *TL1A* in tumorigenesis of GC, we screened the differentially expressed genes (DEGs) and co-expressed genes associated with *TL1A* in GC. Subsequently, we performed gene set enrichment analysis (GSEA) to obtain the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway. Finally, we constructed a *TL1A*-related miRNA-lncRNA/mRNA network and predicted the prognostic value of *TL1A* in GC.

Materials and methods {#S0002}
=====================

Data collection {#S0002-S2001}
---------------

Clinical and survival data from 418 patients with GC were retrieved from The Cancer Genome Atlas (TCGA) through the Genomic Data Commons (GDC) portal. Further, 375 tumor samples and 50 normal tissues samples with the RNA-seq gene expression data (HTSeq--Counts) were included in the present study. All data in our study were downloaded from the database of University of California Santa Cruz (UCSC) xena (<https://xenabrowser.net>).

Data preprocessing and differential expression analysis {#S0002-S2002}
-------------------------------------------------------

Since the downloaded RNA-seq expression profile data were converted logarithmically, we first transformed it into a read count generated by normal HTSeq software.[@CIT0013] In addition, the edgeR package[@CIT0014] was used to screen the DEGs between GC tissues samples and normal controls in the expressing data. Next, information on the obtained genes was supplemented by combining the gene annotation information in GENCODE database.[@CIT0015]

Identification of co-expression gene of TL1A and GSEA {#S0002-S2003}
-----------------------------------------------------

Pearson's correlation matrices were performed for the analysis of the correlation between *TL1A* and other genes. Genes with correlation coefficients \>0.5 (*P*\<0.01) were considered to have co-expressed relationship with *TL1A*. Moreover, according to gene-type information, lncRNA was selected as the key gene for downstream analysis.

To obtain the KEGG pathway associated with *TL1A*, we conducted GSEA, as previously described,[@CIT0016] based on the background of all the genes. Results with ES \>0.5, NES \>1.7 and *P*-value \<0.05 were regarded as significant. Gene sets derived from the enrichment analysis were integrated with mRNA from the co-expression analysis to identify overlapped genes as key genes.

Construction of the tl1a-related miRNA-lncRNA/mRNA network {#S0002-S2004}
----------------------------------------------------------

In order to construct the miRNA-lncRNA/mRNA network based on the relationship between miRNA and lncRNA or mRNA, we downloaded the lncRNA transcript sequence, mRNA sequence of 3ʹUTR and mature miRNA sequences from the Ensembl database to predict the relationship between miRNA and lncRNA or mRNA using miRanda.[@CIT0017] Furthermore, the interactions were in accordance with the following criteria: 1) miRNA had a regulatory relationship with *TL1A*; 2) miRNA simultaneously regulated both mRNA and lncRNA; and 3) miRNA regulated more than 10 mRNAs or lncRNAs. Next, Cytoscape was used to construct and visualize the miRNA-lncRNA/mRNA regulatory network.[@CIT0018]

Validation of DEGs based on clinical samples and cell lines {#S0002-S2005}
-----------------------------------------------------------

For further validation of our findings, *TL1A* expression levels were also determined in clinical 10 GC tissues samples and corresponding adjacent normal samples from the Affiliated Hospital of Chengde Medical College, as well as normal human stomach cells GES-1 and a panel of GC cells (AGS, BGC823, MGC803, SGC7901, and HGC27), which were purchased from the Chinese Academy of Sciences, Shanghai, China. This study was approved by the Ethical Committee of Affiliated Hospital of Chengde Medical College, and all patients signed informed consents.

Total RNA from tissues and cells were extracted using Trizol reagent (Invitrogen). First-strand cDNA was generated using Reverse Transcription Reagents (Takara RR047) according to the manufacturer's protocol. Real-time qPCR was performed in the Real-Time PCR Detection System (Bio-Rad) using SYBR Green (Takara RR820). Primer sequences were as follows: *TL1A*, F: 5′-TTAGAGCAGACGGAGATAAGCCAAG-3′; R: 5′-CCTAGTTCATGTTCCCAGTGCAGA-3′ and β-actin, F: 5′-AGCGAGCATCCCCCAAAGTT-3′; R: 5′-GGGCACGAAGGCTCATCATT-3′. Relative expression of *TL1A* normalized to β-actin was calculated with the 2^--ΔΔ^Ct method.

Survival analysis {#S0002-S2006}
-----------------

To evaluate the prognostic value of the screened genes, survival analysis was performed, and to improve the reliability of the results with larger samples, we performed a KM plot analysis (<http://kmplot.com>) using a JetSet best probe set (Only including HGU133 PLUS 2.0 microarray data), based on the datasets, GSE14210, GSE15459, GSE22377, GSE29272, GSE51105, and GSE62254. A *P*\<0.05 was considered statistically significant.

Results {#S0003}
=======

Expression pattern of TL1A in GC {#S0003-S2001}
--------------------------------

As shown in [Figure 1](#F0001){ref-type="fig"}, multidimensional scaling (MDS) analysis of the samples revealed that the tumor samples were concentrated in the middle of the image in compared to the normal controls. Moreover, *TL1A* expression in GC samples was higher than that in normal controls (Log FC =1.07), and the difference was significant (*P*=8.90E-07; [Table 1](#T0001){ref-type="table"}).Table 1The information of TL1ACategoriesTermsGene_idENSG00000181634.7Gene_nameTNFSF15Gene_typeprotein_codingGene_statusKNOWNLevel2Chromechr9Start1.15E+08End1.15E+08Strand--Log FC1.073987Log CPM4.415753LR24.15204*P*-value8.90E-07FDR8.01E-06[^2] Figure 1Multidimensional scaling (MDS) analysis of samples. Compared to normal tissue samples (green circle), tumor samples (red square) were concentrated in the center of the image.

Co-expression analysis {#S0003-S2002}
----------------------

A total of 215 genes co-expressed with *TL1A* were obtained after Pearson's correlation analysis. As illustrated in [Table 2](#T0002){ref-type="table"}, the top ten genes more closely correlated with *TL1A*, including caspase 10 (*CASP10*), iodotyrosine deiodinase (*IYD*), major vault protein (*MVP*), g protein-coupled receptor class c group 5 member A (*GPRC5A*), solute carrier family 45 member 4 (*SLC45A4*), interferon gamma receptor 1 (*IFNGR1*), rho guanine nucleotide exchange factor 5 (*ARHGEF5*), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta (*PIK3CB*), lymphocyte antigen 75 (*LY75*), and caspase 8 (*CASP8*) were identified (all, *P*\<0.05).Table 2Analysis of co-expression genes with TL1A (top 10)Gene IDGene nameGene_typeCor*P*-valueadj. *p*ENSG00000003400.13*CASP10*protein_coding0.5860836.59E-395.13E-35ENSG00000009765.13*IYD*protein_coding0.5224486.98E-303.80E-27ENSG00000013364.17*MVP*protein_coding0.5045881.12E-273.57E-25ENSG00000013588.5*GPRC5A*protein_coding0.5624242.53E-356.65E-32ENSG00000022567.8*SLC45A4*protein_coding0.5174922.94E-291.37E-26ENSG00000027697.11*IFNGR1*protein_coding0.5010952.93E-278.54E-25ENSG00000050327.13*ARHGEF5*protein_coding0.5388594.99E-325.45E-29ENSG00000051382.7*PIK3CB*protein_coding0.5071035.58E-281.93E-25ENSG00000054219.10*LY75*protein_coding0.5605534.73E-351.14E-31ENSG00000064012.20*CASP8*protein_coding0.5501151.43E-332.35E-30[^3]

Functional prediction based on GSEA {#S0003-S2003}
-----------------------------------

We performed GSEA to identify the potential function of the screened DEGs. A total of 21 KEGG pathways were enriched (ES \>0.5, NES \>1.7, *P*\<0.05; [Table 3](#T0003){ref-type="table"}). Furthermore, based on the enriched gene sets and the genes from the co-expression analysis, we identified the intersection genes as the key genes that are relevant to the disease progression of GC. Moreove[r]{.ul}, the relationships between the intersection genes and the enriched KEGG pathway were visualized as interaction networks ([Figure 2](#F0002){ref-type="fig"}).Table 3KEGG pathways significantly enriched from GSEAKEGGSizeESNESNOM *p*-valRIG I like receptor signaling pathway700.6297481.9813770ABC transporters440.6149371.8644730.0018622Cytosolic DNA sensing pathway550.5829421.833470.00566038Glycosylphosphatidylinositol GPI anchor biosynthesis250.7550471.7954870.00782779Glycerophospholipid metabolism760.5854791.7771310.01529637Regulation of autophagy350.5318911.7071490.01651376JAK-STAT signaling pathway1510.5233951.7369790.01792829NOD like receptor signaling pathway610.6280861.7591420.01901141Fc gamma r mediated phagocytosis960.6094631.745320.02294455N-Glycan biosynthesis460.7073221.7297330.02385686O-Glycan biosynthesis270.6262631.7375380.02420857Sphingolipid metabolism390.6241621.745330.02830189Leukocyte transendothelial migration1160.5495861.7347660.02868069Phosphatidylinositol signaling system760.6076891.71780.02929688Tight junction1300.5239881.7125780.03201507Lysosome1190.6489341.7526030.03333334Epithelial cell signaling in *Helicobacter pylori* infection670.5995251.7213980.03578154Apoptosis860.6116041.7603690.03591682Axon guidance1280.5459021.7062590.04339623 Figure 2Relationship between KEGG pathway and enrichment genes from GSEA. Red diamond represents enriched KEGG pathway, while the blue circular node represents the enriched gene of the related pathway.

Construction of miRNA-lncRNA/mRNA network {#S0003-S2004}
-----------------------------------------

Based on the above data, the miRNA-lncRNA/mRNA network was constructed using Cytoscape. As illustrated in [Figure 3](#F0003){ref-type="fig"}, the miRNA-lncRNA/mRNA network was composed of 7 miRNA nodes, 27 lncRNA nodes, and 21 mRNA nodes.Figure 3The miRNA-lncRNA/mRNA network in GC. Blue triangles represent miRNA. Orange diamonds represent lncRNA. Circles represent mRNA.

Identification of survival-related lncRNAs in GC {#S0003-S2005}
------------------------------------------------

In order to investigate the genes associated with the survival of GC patients, 876 patients were divided into the high and low groups based on the gene expression median. The results showed that the patients with high *TL1A* levels had shorter overall survival (OS) than those with low expression (*P*=2.6e−07; [Figure 4A](#F0004){ref-type="fig"}). Similarly, SRC Proto-Oncogenes (*SRC*) were positively correlated with the OS of GC patients, respectively (*P*=0.0081; [Figure 4B](#F0004){ref-type="fig"}).Figure 4Survival analysis using the Kaplan-Meier curve. Patients with high expression of *TL1A* (**A**) and SRC (**B**) had worse OS than those with low expression.

Validation of TL1A in clinical tissue samples and cell lines {#S0003-S2006}
------------------------------------------------------------

To confirm the reliability of the *TL1A* identified *in silico*, the *TL1A* expression profiles were verified in tissue samples and cell lines. *TL1A* levels in ten GC tissues were all higher than those in adjacent normal samples ([Figure 5](#F0005){ref-type="fig"}), which is in accordance with the data above. Similarly, *TL1A* expression in GC cell lines were all significantly upregulated compared to that in normal cell lines (all, *P*\<0.05).Figure 5*TL1A* expression is determined by qRT-PCR. The *TL1A* mRNA levels in GC tissues (**A**) and cell lines (**B**) were higher than those in normal tissue samples and cell lines. \**P*\<0.05 and \*\**P*\<0.01.

Discussion {#S0004}
==========

Despite developments in GC treatment, its prognosis remains frustratingly poor. Hence, the identification of risk factors and accurate prognostic prediction in GC patients is still urgent. In this study, we determined the clinical significance of *TL1A* in GC progression based on TCGA database. The results showed that *TL1A* expression in GC tissues samples was significantly increased compared to that in normal controls. Moreover, a set of co-expressed genes, enriched genes, and KEGG pathways were obtained. Then, the miRNA-lncRNA/mRNA network was constructed that provided an integrated view of RNA regulation. After a series of bioinformatics analyses, *TL1A* was identified to be associated with the progression and prognosis of GC.

In fact, as a counter-balancing factor in the maintenance of vascular integrity, *TL1A* has been found to be abnormally expressed in multiple tumor types.[@CIT0019],[@CIT0020] Moreover, Qin et al[@CIT0021] reveals that *TL1A* could promote lymphatic metastasis of lung cancer cells via VEGFC up-regulation. These studies suggest that *TL1A* may play an important role in tumorigenesis, and in accordance with them, our results, based on the data from TCGA database, suggest that *TL1A* expression levels in GC tissue samples increased significantly when compared to normal controls. Furthermore, the validation analysis showed that TL1A expression was upregulated in other clinical GC tissue samples and cell lines. In addition, co-expression analysis detected 215 genes that were co-expressed with *TL1A*. Among these co-expressed genes, CASP10 is reported to be associated with the risk of GC,[@CIT0022] and GPRC5A overexpression could predict the advanced poor prognosis in patients with GC.[@CIT0023] All these results suggested that TL1A, along with a series of co-expressed genes are involved in the development of GC; however, the mechanism of function still requires further investigation.

Recent studies suggest *TL1A* can suppress proliferation and induce apoptosis of endothelial cells through different signaling pathways.[@CIT0024],[@CIT0025] Based on KEGG pathway analysis with GSEA, some cancer-related pathways, such as the phosphatidylinositol, NOD-like receptor (NLR), and JAK-STAT signaling pathways, were determined, indicating that *TL1A* may play an important role in GC development through different pathways. Chiappini et al[@CIT0026] reported the prognostic implications of the phosphatidylinositol signaling pathway activation in GC. Castaño-Rodríguez et al[@CIT0027] highlighted the relationship between the NLR signaling pathway and gastric carcinogenesis. Additionally, the involvement of the JAK-STAT signaling pathway in gastric carcinogenesis has been reported.[@CIT0028],[@CIT0029] Hence, via pathway analysis, we further verified that *TL1A* might be an important factor in GC development.

Until now, few studies have investigated the interaction between miRNA and lncRNAs, or miRNAs and mRNAs in GC. In this study, we constructed a miRNA-lncRNA/mRNA network with 7 miRNAs, 27 lncRNAs, and 21 mRNAs, which provided an integrated view of the regulatory crosstalk among these genes associated with *TL1A* in GC. More importantly, *TL1A*, along with SRC, were all found to be significantly associated with the survival of GC patients. Specifically, patients with high expression levels of *TL1A*, or *SRC* had shorter survival times than those with low expression. In fact, accumulating evidence indicates that *TL1A* was associated with GC prognosis.[@CIT0011],[@CIT0030] SRC, a nonreceptor tyrosine kinase that acts downstream of receptor tyrosine kinases, is involved in cell proliferation migration, adhesion, and invasion.[@CIT0031] Elsberger et al[@CIT0032] reported that high expression levels of cytoplasmic *SRC* was associated with a worse prognosis of luminal-type breast cancer, which is in accordance with our studies.

Conclusion {#S0005}
==========

In conclusion, we identified that *TL1A* was aberrantly expressed in GC; meanwhile, a set of genes co-expressed with *TL1A*, and pathways were detected. Furthermore, we constructed the miRNA-lncRNA/mRNA network, and identified that *TL1A* was correlated with OS in GC patients. To our knowledge, this is the first study to evaluate the function of *TL1A* in the tumorigenesis and progression of GC. However, the clinical value of *TL1A* for targeted GC therapy and prognosis still needs to be verified.
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